Figures & data
Figure 1 Study design.
Abbreviations: LAMA, long-acting muscarinic antagonist; SMI, soft mist inhaler; DPI, dry powder inhaler.
Figure 2 Patient identification and attrition.
Abbreviations: SMI, soft mist inhaler; DPI, dry powder inhaler; COPD, chronic obstructive pulmonary disease; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; Rx, prescription.
Table 1 Baseline Patient Characteristics, by Inhaler Type, Before and After IPTW
Table 2 Baseline COPD-Related HRU and Acute COPD-Related Exacerbations
Figure 3 Follow-up HRU post-IPTW, by inhaler type: SMI (n=5360) and DPI (n=22,880), PPPM.
Note: No significant differences were observed.
Abbreviations: IPTW, inverse probability of treatment weighting; SMI, soft mist inhaler; DPI, dry power inhaler; PPPM, per patient per month; ED, emergency department.
Figure 4 Follow-up COPD acute exacerbations after IPTW by inhaler type: SMI (n=5360) and DPI (n=22,880).
Abbreviations: IPTW, inverse probability of treatment weighting; SMI, soft mist inhaler; DPI, dry power inhaler; PPPM, per patient; ED, emergency department.
